Meeting primary safety and efficacy endpoints in a clinical study is a significant milestone for any medical device company. This success suggests that LivaNova's treatment for obstructive sleep apnea is effective and safe, which could lead to regulatory approval and commercialization. This positive news is likely to boost investor confidence and positively impact LIVN's stock price in the short term.